Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00524264 · ClinicalTrials.gov registry record · Phase 3

A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

A Phase 3 study of Pain and Inflammation, sponsored by Allergan.

Completed
Registry status
Phase 3
Development phase
248
Enrollment target
1
Study location

NCT00524264 is a Phase 3 study of Pain and Inflammation that has completed, run by Allergan. The registered enrollment target is 248 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00524264, a Phase 3 study of Pain and Inflammation, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 3
Development phase
248 participants
Enrollment target
1
Study location

Study Summary

This is a 16-day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery.

Interventions

  • DRUG ketorolac

Study Locations (1)

California

  • - Artesia

Trial Details

FieldValue
Enrollment Target 248 participants
Start Date 2007-10
Est. Completion 2008-04
Phase Phase 3

Sponsor

Allergan

314 total trials

What the Registry Record Tells You About NCT00524264

The ClinicalTrials.gov registry entry for NCT00524264 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (18% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which ketorolac is the first listed.

NCT00524264 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00524264 about?

NCT00524264 is a clinical study titled "A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery". This is a 16-day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery.

What is the current status of trial NCT00524264?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 248 participants. The study started on 2007-10. Estimated completion is 2008-04.

What conditions does trial NCT00524264 study?

This clinical trial studies the following conditions: Pain, Inflammation, Cataract Extraction.

What interventions are being tested in trial NCT00524264?

The interventions under investigation include: ketorolac (DRUG).

Who is sponsoring clinical trial NCT00524264?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00524264 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.